Stereotaxis, Inc. (STXS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Stereotaxis, Inc. designs, manufactures, and markets robotic systems (Genesis RMN System) and information systems (Odyssey Solution) for interventional laboratories, primarily focusing on cardiac ablation procedures. The company utilizes Robotic Magnetic Navigation to control catheter tips. As of July 31, 2024, the company completed the acquisition of Access Point Technologies EP, Inc. (APT), a manufacturer of diagnostic catheters.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $11,382 |
| Gross Margin | $7,279 (64% of revenue) |
| Operating Loss | $(10,767) |
| Net Loss | $(10,340) |
| Net Loss Attributable to Common Stockholders | $(10,996) |
| Cash and Cash Equivalents | $14,683 |
| Total Cash (incl. Restricted) | $15,164 |
| Working Capital | $15,820 |
| Debt | $0 (No debt outstanding) |
| Net Cash Used in Operating Activities | $(5,434) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 21% year-over-year (from $14.4M to $11.4M) for the six-month period. System revenue dropped significantly from $5.1M to $2.9M due to lower sales volumes. Disposables and service revenue decreased 8% to $8.5M.
- Margin Expansion: Despite lower revenue, gross margin percentage improved to 64% (from 56% in 2023) due to a favorable shift in product mix toward higher-margin disposables and services.
- Expense Management: Research and Development (R&D) expenses decreased 16% to $4.5M, driven by a $0.5M reversal of an accrued regulatory fee and reduced headcount. General and Administrative (G&A) expenses increased slightly by 2% to $7.2M due to higher professional service fees.
- Liquidity: Cash balances decreased from $20.6M at year-end 2023 to $15.2M at June 30, 2024, primarily due to operating cash outflows.
Outlook, Risks, and Unusual Items
- Acquisition of APT: On July 31, 2024, Stereotaxis acquired APT for an upfront payment of 1,486,620 shares of common stock. The deal includes contingent earn-out payments based on revenue and regulatory milestones through 2029, which could result in significant future dilution (estimated up to ~6.1M shares total).
- CEO Performance Award: A significant portion of stock-based compensation ($3.6M for the six months) relates to a 2021 CEO Performance Award tied to market capitalization milestones. As of June 30, 2024, no milestones have been achieved, and approximately $33.4M in unrecognized expense remains.
- Risks: The company faces risks related to the integration of APT, supply chain disruptions, inflationary pressures, and the ability of hospital customers to secure capital for large system purchases. There is also a risk of customer defaults or payment delays.
- Legal: A vendor filed a UCC financing statement on inventory valued at approximately $0.6M in February 2024; the company is contesting this action as without merit.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost implications of integrating APT's catheter manufacturing capabilities, given Stereotaxis's limited prior experience in this specific area.
- Dilution Impact: Assess the potential dilution from the APT earn-out shares (up to ~4.6M additional shares) and the ongoing CEO Performance Award.
- System Sales Pipeline: Confirm the status of the $15.3M in remaining performance obligations for system contracts and the outlook for capital system sales given hospital capital constraints.
- Cash Burn Rate: Monitor the net cash burn of approximately $5.4M per six months against the current cash balance of $15.2M to determine runway without additional financing.
- Regulatory Milestones: Track progress on regulatory approvals for the MAGiC catheter and APT products, as these are critical for future revenue growth and earn-out triggers.